|
Market Closed -
London S.E.
02:35:19 09/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 11,892.00 GBX | -2.36% |
|
-1.16% | -13.76% |
| 02:56am | European Stocks Close Lower in Thursday Trading Amid Surging Oil Prices, Bond Yields | MT |
| 02:36am | Rising oil prices weigh on Stockholm exchange, OMXS30 index falls 0.8 percent | FW |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 249,498 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -13.31% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 269,537 | 261,846 | 253,175 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -13.38% | -2.85% | -3.31% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 20.8x | 17.8x | 15.8x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 4.61x | 4x | 3.44x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.1x | 1.1x | 1.3x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 3.95x | 3.72x | 3.51x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.27x | 3.91x | 3.56x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 12.2x | 10.8x | 9.43x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 12.8x | 11.3x | 9.92x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 28.1x | 20.2x | 17.3x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.56% | 4.95% | 5.77% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.34 | 3.544 | 3.655 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 2.08% | 2.2% | 2.27% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.738 | 9.041 | 10.18 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 43.2% | 39.2% | 35.9% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,161 | 67,050 | 71,117 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,090 | 24,352 | 26,857 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,050 | 23,192 | 25,510 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 11,903 | 13,857 | 15,560 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 20,039 | 12,348 | 3,677 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 160.86 | 160.86 | 160.86 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 10/2/22 | 9/2/23 | 8/2/24 | 6/2/25 | 10/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.79x | 4.27x | 12.2x | 2.08% | 249B | |
| 33.76x | 12.26x | 24.76x | 0.58% | 1,060B | |
| 28.75x | 6.35x | 18.21x | 2.07% | 623B | |
| 34.38x | 7.99x | 16.52x | 2.56% | 480B | |
| 103.88x | 5.82x | 24.82x | 2.39% | 352B | |
| 19.43x | 4.75x | 11.8x | 2.78% | 345B | |
| 20.28x | 5.28x | 13.08x | 3.01% | 274B | |
| 26.09x | 6.8x | 12.11x | 2.44% | 223B | |
| -44.42x | 6.54x | 25.48x | 2.24% | 182B | |
| 11.3x | 4.13x | 8.62x | 4.49% | 168B | |
| Average | 25.42x | 6.42x | 16.76x | 2.46% | 395.61B | |
| Weighted average by Cap. | 31.30x | 7.68x | 18.64x | 2.02% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
